CL2020000363A1 - Inhibidores macrocíclicos de mcl-1 y métodos de uso. - Google Patents
Inhibidores macrocíclicos de mcl-1 y métodos de uso.Info
- Publication number
- CL2020000363A1 CL2020000363A1 CL2020000363A CL2020000363A CL2020000363A1 CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1 CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitors
- methods
- mcl
- macrocyclic
- macrocyclic mcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA PRESENTE DIVULGACIÓN SE REFIERE A INHIBIDORES DE LA PROTEÍNA DE DIFERENCIACIÓN CELULAR DE LEUCEMIA 5 MIELOIDE INDUCIDA (MCL-1), EN DONDE A2, A3, A4, A6, A7, A8, A15, RA, R5, R10A, R10B, R11, R12, R13, R14, W, X, E Y TIENEN CUALQUIERA DE LOS VALORES DEFINIDOS EN LA MEMORIA DESCRIPTIVA, Y SALES ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO DE ESTOS , QUE SON ÚTILES COMO AGENTES EN EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES, INCLUIDO EL CÁNCER. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA FÓRMULA (I) .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762545853P | 2017-08-15 | 2017-08-15 | |
US201762555475P | 2017-09-07 | 2017-09-07 | |
US201862692663P | 2018-06-30 | 2018-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000363A1 true CL2020000363A1 (es) | 2020-06-12 |
Family
ID=65362347
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000363A CL2020000363A1 (es) | 2017-08-15 | 2020-02-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. |
CL2020002943A CL2020002943A1 (es) | 2017-08-15 | 2020-11-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002943A CL2020002943A1 (es) | 2017-08-15 | 2020-11-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 |
Country Status (21)
Country | Link |
---|---|
US (3) | US10676485B2 (es) |
EP (2) | EP3652184A4 (es) |
JP (1) | JP2020531433A (es) |
KR (1) | KR20200041942A (es) |
CN (1) | CN111818917A (es) |
AU (1) | AU2018316620A1 (es) |
BR (1) | BR112020003180A2 (es) |
CA (1) | CA3073112A1 (es) |
CL (2) | CL2020000363A1 (es) |
CO (1) | CO2020002678A2 (es) |
CR (1) | CR20200124A (es) |
EC (1) | ECSP20018703A (es) |
IL (1) | IL272681A (es) |
MX (1) | MX2020001717A (es) |
PH (1) | PH12020500327A1 (es) |
RU (1) | RU2020110517A (es) |
SG (2) | SG10202106345VA (es) |
TW (1) | TW201920194A (es) |
UA (1) | UA126586C2 (es) |
UY (1) | UY37843A (es) |
WO (1) | WO2019035911A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11414390B2 (en) | 2017-09-07 | 2022-08-16 | Hutchison Medipharma Limited | Cycloolefin substituted heteroaromatic compounds and their use |
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111818917A (zh) * | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
TW201920193A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環mel-1抑制劑以及使用方法 |
WO2019035865A1 (en) | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals Inc. | MODULATORS OF PYRUVATE KINASE AND THEIR USE |
US20200255451A1 (en) * | 2017-08-15 | 2020-08-13 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
KR20220017931A (ko) | 2019-05-20 | 2022-02-14 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
WO2022115451A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
TW202315637A (zh) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2276346B1 (en) * | 2008-04-30 | 2016-11-23 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
LT3532067T (lt) | 2016-10-28 | 2022-08-25 | Les Laboratoires Servier | Liposominė vaisto forma, skirta naudoti gydant vėžį |
EP3567043B1 (en) | 2017-01-05 | 2023-12-06 | Henan Genuine Biotech Co., Ltd. | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer |
UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
TW201920193A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環mel-1抑制劑以及使用方法 |
CN111818917A (zh) * | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
US20200255451A1 (en) | 2017-08-15 | 2020-08-13 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
CN107573360B (zh) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
-
2018
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/zh active Pending
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/ko not_active Application Discontinuation
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/ja active Pending
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 EP EP18846737.7A patent/EP3652184A4/en not_active Withdrawn
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/es unknown
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/pt not_active IP Right Cessation
- 2018-08-15 UY UY0001037843A patent/UY37843A/es not_active Application Discontinuation
- 2018-08-15 TW TW107128523A patent/TW201920194A/zh unknown
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/ru unknown
- 2018-08-15 CR CR20200124A patent/CR20200124A/es unknown
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en unknown
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 UA UAA202001749A patent/UA126586C2/uk unknown
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/es unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/es unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/es unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/es unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11414390B2 (en) | 2017-09-07 | 2022-08-16 | Hutchison Medipharma Limited | Cycloolefin substituted heteroaromatic compounds and their use |
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US10676485B2 (en) | 2020-06-09 |
IL272681A (en) | 2020-03-31 |
RU2020110517A3 (es) | 2022-03-23 |
EP3652184A1 (en) | 2020-05-20 |
KR20200041942A (ko) | 2020-04-22 |
CN111818917A (zh) | 2020-10-23 |
PH12020500327A1 (en) | 2020-10-12 |
US20190144465A1 (en) | 2019-05-16 |
SG11202001182QA (en) | 2020-03-30 |
BR112020003180A2 (pt) | 2020-09-15 |
TW201920194A (zh) | 2019-06-01 |
RU2020110517A (ru) | 2021-09-16 |
UA126586C2 (uk) | 2022-11-02 |
ECSP20018703A (es) | 2020-04-22 |
WO2019035911A1 (en) | 2019-02-21 |
CL2020002943A1 (es) | 2021-03-12 |
EP3652184A4 (en) | 2020-05-20 |
MX2020001717A (es) | 2020-10-08 |
EP3988555A1 (en) | 2022-04-27 |
JP2020531433A (ja) | 2020-11-05 |
CO2020002678A2 (es) | 2020-08-10 |
CA3073112A1 (en) | 2019-02-21 |
SG10202106345VA (en) | 2021-07-29 |
US20200325153A1 (en) | 2020-10-15 |
UY37843A (es) | 2019-03-29 |
US20230183261A1 (en) | 2023-06-15 |
AU2018316620A1 (en) | 2020-03-12 |
CR20200124A (es) | 2020-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000363A1 (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso. | |
CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
DOP2022000117A (es) | Inhibidores de kras g12c | |
PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
CO2018011064A2 (es) | Inhibidores de bromodominios | |
UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
DOP2015000305A (es) | Inhibidores de bromodominios | |
UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
UY37844A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
MX2015012005A (es) | Inhibidores de bromodominio. | |
CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
CY1121060T1 (el) | Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση | |
MX2019004375A (es) | Inhibidores de bromodominios. | |
MX2019004187A (es) | Inhibidores de bromodominios. | |
EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 |